Hormone plus chemo combo aims to outsmart resistant prostate cancer
NCT ID NCT03522064
First seen May 01, 2026 · Last updated May 01, 2026
Summary
This study tests whether giving high-dose testosterone along with the chemotherapy drug carboplatin can help men whose advanced prostate cancer has stopped responding to standard hormone therapy. About 30 men with a specific genetic mutation (HRD) will receive the treatment. The goal is to see if this approach can lower PSA levels and control the cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HOMOLOGOUS RECOMBINATION DEFICIENCY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Kinghorn Cancer Centre, St. Vincent's Hospital
RECRUITINGSydney, New South Wales, 2010, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.